

NCT ID	NCT05491317
Title	A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
Phase	Phase 1, Phase 2
Date Added	2022-08-08
Location	France
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Pembrolizumab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05487235
Title	A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Phase	Phase 1
Date Added	2022-08-04
Location	Argentina Australia Brazil Canada Korea, Republic of New Zealand
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Atezolizumab, GDC-1971, Omeprazole
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05482516
Title	Evaluating Novel Therapies in ctDNA Positive GI Cancers
Phase	Phase 3
Date Added	2022-08-01
Location	District of Columbia, United States New Jersey, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Atezolizumab, Bevacizumab, Avastin, Tecentriq
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05479812
Title	Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
Phase	Phase 1
Date Added	2022-07-29
Location	Arizona, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States New Jersey, United States New York, United States Oregon, United States Texas, United States

Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Pembrolizumab, WTX-124
Tags	MSI-H/ MMRd
<hr/>	
NCT ID	NCT05480306
Title	Phase 2 Study of DKN-01 in Colorectal Cancer
Phase	Phase 2
Date Added	2022-07-29
Location	Arizona, United States California, United States Florida, United States Louisiana, United States Maryland, United States Missouri, United States New York, United States North Carolina, United States South Carolina, United States South Dakota, United States Tennessee, United States Washington, United States Wisconsin, United States Germany Korea, Republic of
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Bevacizumab, DKN-01, FOLFIRI, FOLFOX
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT05464030
Title	Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
Phase	Phase 1
Date Added	2022-07-19
Location	California, United States Rhode Island, United States Texas, United States Canada Japan Korea, Republic of Spain
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	M9140
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT05438342
Title	An Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis
Phase	Not Applicable
Date Added	2022-06-29
Location	China
Prior IO Allowed	Yes
CRC-directed	No

Status	Recruiting
Drugs	Chemotherapy?checkpoint immunotherapy, targeted therapy
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT05426005
Title	Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
Phase	Phase 1, Phase 2
Date Added	2022-06-21
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Cadonilimab
Tags	MSI-H/ MMRd
NCT ID	NCT05425940
Title	Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303)
Phase	Phase 3
Date Added	2022-06-21
Location	Alabama, United States Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Louisiana, United States Missouri, United States Montana, United States Nebraska, United States New Mexico, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Virginia, United States Washington, United States Australia Belgium France Germany Hong Kong Hungary Korea, Republic of New Zealand Poland Portugal Singapore Spain Taiwan Thailand United Kingdom
Prior IO Allowed	No

CRC-directed	Yes
Status	Active, not recruiting
Drugs	Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Regorafenib, XL092, Stivarga, Tecentriq
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT05409417
Title	Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status
Phase	Phase 2
Date Added	2022-06-08
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Unknown status
Drugs	Bevacizumab, cetuximab, FOLFOX, Tislelizumab, XELOX
Tags	MSS/ MMRp